Home World News No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line... World News No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC By Ogkologos - March 3, 2026 391 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SONIA study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Welcome to our new committee chairs November 22, 2022 Gene Tied to Alzheimer’s May Be Associated with Cancer-Related Cognitive Problems November 9, 2018 European Lung Cancer Congress 2024 March 7, 2024 Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR,... July 16, 2025 Load more HOT NEWS Predicting future breast cancer with precision Dual-Function Virus Engineered to Kill Tumor Cells and Support Immune Cells Blinatumomab Improves Survival in Children with Relapsed Leukemia Targeted prostate cancer screening: Are we there yet?
